Jonsson to succeed Mason as head of Lilly Diabetes and Obesity
Plus: Grabulovski takes over as CEO of Araris and updates from IGM, Odyssey, Alpine, Nuvig, Rome, Saghmos, Nature’s Toolbox and Myricx
Mike Mason is retiring from Eli Lilly and Co. (NYSE:LLY) as EVP and president of Lilly Diabetes and Obesity at year-end after a 34-year tenure, during the past four years of which he has overseen the late-stage development and launch of blockbuster Mounjaro tirzepatide. Patrik Jonsson will succeed him, adding to his role of EVP and president of Lilly USA while handing over leadership of Lilly Immunology to CSO and President of Lilly Research Laboratories Daniel Skovronsky.
Lilly also said that David Hyman will become CMO while continuing to oversee oncology development, and Leigh Ann Pusey will retire at year-end as EVP of corporate affairs and communications. Additional moves include Jennifer Oleksiw’s promotion to group vice president, global chief customer officer and the hiring of Mark Genovese as SVP, immunology development. Genovese, who was SVP of inflammation development at Gilead Sciences Inc. (NASDAQ:GILD), will join Lilly on Oct. 16. Pusey’s responsibilities will be split between Lilly’s executive committee members. ...